EVAX Evaxion A/S
Price Chart
Executive Summary
Evaxion announced it received the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform. This is a non-financial, non-regulatory recognition that provides external validation of the company's AI platform but does not change its clinical or financial trajectory. The filing is a routine press release with no material financial data or operational updates.
Actionable Insight
This award is a reputational positive but does not alter Evaxion's clinical or financial outlook. Traders should monitor upcoming clinical data readouts and capital-raising activities for material catalysts. The stock's historical underperformance following prior neutral reports suggests limited near-term price reaction to this type of news.
Key Facts
- Evaxion received the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform.
- The award was presented at a ceremony at the Natural History Museum in London.
- This is the second recognition from the Galien Prix Foundation in less than a year; the first was in December 2025 for Best Medical Technology / AI Advances in the Nordic and high-growth European and Middle Eastern countries.
- The jury evaluated innovation in scientific development, clinical application, utility, insights in biomedical science, and tangible impact on human health.
- No financial figures, clinical data, guidance, or material operational changes were disclosed in the filing.
Financial Impact
No financial impact disclosed; award is non-monetary and non-regulatory.
Risk Factors
- Award does not accelerate clinical timelines or regulatory approvals.
- No improvement in financial position or reduction in cash burn risk.
- Market may view this as a non-material event given the company's pre-revenue status and need for additional capital.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004073 |
| Exhibit: exh_991.htm | 0001171843-26-004073 |
| Document: 0001171843-26-004073-index-headers.html | 0001171843-26-004073 |
| Document: 0001171843-26-004073-index.html | 0001171843-26-004073 |
| Document: 0001171843-26-004073.txt | 0001171843-26-004073 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
6-K
| $3.71 awaiting T+5 | awaiting T+5 | — | $3.64 (−1.89%) |
|
Jun 12, 2026
3d ago
|
Press Release
| $3.71 awaiting T+5 | awaiting T+5 | — | $3.64 (−1.89%) |
|
Jun 11, 2026
3d ago
|
6-K
| $3.72 awaiting T+5 | awaiting T+5 | — | $3.64 (−2.15%) |
|
Jun 11, 2026
4d ago
|
Press Release
| $3.72 awaiting T+5 | awaiting T+5 | — | $3.64 (−2.15%) |
|
May 12, 2026
4w ago
|
6-K
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.64 (−12.71%) |
|
May 12, 2026
4w ago
|
Press Release
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $3.64 (−12.71%) |
|
May 7, 2026
5w ago
|
6-K
| $4.07 $4.16 | ▲ +2.21% | ▲ +0.71% | $3.64 (−10.57%) |
|
May 4, 2026
5w ago
|
Press Release
| $4.57 $4.23 | ▼ −7.55% | ▼ −10.49% | $3.64 (−20.35%) |
|
Apr 27, 2026
6w ago
|
6-K
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.64 (−12.92%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $3.64 (−12.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access